[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
For patients undergoing cancer chemotherapy, sufficient supportive antiemetic therapy is important for maintaining the quality of life. Although there are many studies on antiemetic support therapy for high emetic risk regimens, studies on moderately emetic risk regimens are scarce. FOLFOX and FOLFIRI are generic regimens for the treatment of advanced colorectal cancer; evidence for antiemetic supportive therapy at the time of this treatment is scarce. In addition, research on patients over 65 years of age is limited. Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy. Aprepitant was used in combination with granisetron and dexamethasone in 14 patients. After 5 days of treatment, complete control rate of emesis was 100%, and complete control rate of nausea was 64.3%. Our results suggest that aprepitant can be used as a safe antiemetic supportive therapy in elderly advanced colorectal cancer patients undergoing FOLFOX and FOLFIRI, as well as granisetron and dexamethasone.